Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
DepressantDihydrocodeine
Dihydrocodeine (DHC) is a semi-synthetic opioid of the morphinan class. It is roughly equipotent to codeine but carries greater direct activity at opioid receptors.[1] It activates mu-opioid receptors, suppressing pain signaling and slowing central nervous system activity.
Dihydrocodeine (DHC) is a semi-synthetic opioid of the morphinan class. It is roughly equipotent to codeine,[1] distinguished by greater intrinsic mu-receptor activity.[2] Dihydrocodeine is a mu-opioid receptor agonist, producing its effects by suppressing pain signaling and depressing central nervous system activity.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
DepressantDeveloped in Germany in 1908 and first marketed in 1911, DHC was created by a simple chemical modification of codeine.[2] It became the standard detoxification agent for heroin-dependent patients in UK community treatment programs.[3] It remains widely prescribed across Europe, though rising overdose fatality data have prompted renewed regulatory scrutiny.[4]
Subjective effects include pain suppression, warmth, mild euphoria, sedation, and a quieting of anxiety. The experience is gentler than morphine — a mild, manageable calm rather than a deep, heavy opioid weight. Nausea, dizziness, and respiratory depression are characteristic unwanted effects.
Dihydrocodeine produces physical and psychological dependence and carries toxicity comparable to low-dose morphine at equivalent doses.[5] The overdose risk is amplified by its active metabolite, dihydromorphine, which binds opioid receptors far more powerfully than the parent drug — rapid metabolizers face heightened danger at standard doses.[6] Over a century of clinical use provides a solid evidence base, though no formal therapeutic index exists.
History[edit]
Discovery
Dihydrocodeine was developed in Germany in 1908 by chemically modifying codeine — a process called hydrogenation that saturates a double bond in the molecule.[2][7] It was first sold commercially in 1911 and adopted quickly across Europe for pain suppression and cough suppression.
Clinical significance
DHC became a standard analgesic on the WHO pain ladder and, in the United Kingdom, the primary agent for detoxifying heroin-dependent patients in community treatment.[3] In Germany it also served as an opioid substitution agent, though compulsive use among people using multiple drugs was documented from the 1960s onward.[8]
Regulation and modern era
Evidence of dependence and misuse led to tighter controls across jurisdictions. Overdose fatality data from England spanning 2001–2020 challenge the long-standing view of DHC as a low-risk opioid,[4] and pharmacovigilance analysis confirmed ongoing signals of abuse and dependence.[9]
The name dihydrocodeine reflects its chemistry: the prefix dihydro- marks where codeine's double bond was saturated. Clinically it is universally called DHC. Its long-standing reputation as a "weak opioid" has shaped prescribing culture for decades — a perception increasingly contradicted by epidemiological data.[4]
Chemistry[edit]
Structural class
Dihydrocodeine belongs to the morphinan chemical family — the same pentacyclic scaffold shared by morphine, codeine, hydrocodone, and oxycodone. It is made by a simple chemical reduction of codeine, saturating a double bond in the molecule.[10] Its molecular formula is C₁₈H₂₃NO₃ (molecular weight 301.4 g/mol).
The most pharmacologically significant structural feature is a methoxy group at position 3 of the molecule. When the body removes that methyl group, DHC is converted to dihydromorphine — a metabolite that binds opioid receptors with roughly 70-fold greater affinity than DHC itself.[6] All pharmaceutical preparations use the single naturally active mirror-image form, most commonly supplied as dihydrocodeine bitartrate.
Pharmacology[edit]
Mechanism of action
DHC activates mu-opioid receptors in the brain and spinal cord, producing pain suppression, euphoria, and sedation.[6][11] Unlike codeine, DHC retains direct receptor activity and does not depend entirely on metabolic conversion to work.[1] It does not significantly affect serotonin signaling,[12] so serotonin-related risks in DHC combinations come from whatever it is paired with.
Pharmacokinetics
After swallowing, approximately 21% of the dose reaches the bloodstream — the rest is broken down by the liver before it can circulate.[13] Peak effects arrive roughly 1.6–1.8 hours after an oral dose, and the drug clears the body over 3.3–4.5 hours.
The liver converts DHC to several metabolites. The most important is dihydromorphine, which binds opioid receptors with roughly 70-fold greater affinity than DHC itself.[6] A further metabolite — DHM-6-O-glucuronide — also carries high opioid activity[14] and accumulates in kidney impairment, prolonging sedation and increasing respiratory risk.[15][16] About 7% of people of European descent cannot produce dihydromorphine,[6] though DHC still provides pain relief for them — unlike codeine, which largely fails without this conversion.[10] Liver disease increases drug exposure and requires dose reduction.[17]
Neuroscience[edit]
Reward and reinforcement
Opioid receptor activation in the brain's reward circuit releases dopamine, producing the warmth and euphoria characteristic of opioid agonists. Both DHC and its metabolite dihydromorphine activate this pathway. Because dihydromorphine binds receptors with roughly 70-fold greater affinity,[6] people who metabolize DHC rapidly likely experience substantially greater reinforcement — and potentially greater addiction risk — than those who do not.
Pain suppression and respiratory risk
DHC suppresses pain signals traveling through the brainstem and spinal cord, an effect confirmed across multiple clinical trials.[18][19][2] The same receptors in brainstem breathing centers also slow respiration — this is the core mechanism behind opioid overdose death. Post-mortem analysis of fatal DHC overdoses consistently shows elevated dihydromorphine concentrations,[20][14] confirming that the metabolite contributes to lethality even when DHC parent levels appear moderate.
Several questions remain unanswered. Whether genetic variation in DHC metabolism produces measurably different subjective reward — and different addiction trajectories — has not been studied in humans. The role of DHM-6-O-glucuronide in prolonged effects, particularly in kidney impairment, lacks characterization.[14] Whether rising DHC-related mortality trends[4] reflect pharmacological factors, prescribing patterns, or changing polydrug use remains unresolved.
Subjective Effects[edit]
Dihydrocodeine produces a warm, enveloping body sensation. Pain recedes. Mental activity quiets into steady contentment rather than stimulation. The pharmacological character is relatively consistent across individuals, though pre-existing pain, anxiety, and opioid tolerance substantially alter perceived intensity.
Within the opioid class, DHC sits closest to codeine in feel — a mild, manageable warmth with modest euphoria. Compared to morphine, the subjective ceiling is lower and the experience qualitatively thinner, lacking the depth and heavy sedation of higher-affinity agonists.
Developed in Germany in 1908 through hydrogenation of codeine, dihydrocodeine was first marketed in 1911 as an analgesic and cough suppressant.[3] It became a mainstay of European pain management and, in the United Kingdom, a primary detoxification agent for heroin-dependent patients in community settings.[4] It remains widely prescribed across Europe, though rising overdose fatality data have prompted renewed regulatory scrutiny.[5]
Subjective effects include analgesia, sedation, euphoria, anxiolysis, and constipation. The experience is one of gentle warmth and quiet contentment — a mild, manageable opioid calm that lacks the depth and weight of stronger agonists like morphine. Nausea, dizziness, and respiratory slowing are characteristic unsought effects.
Dihydrocodeine produces physical and psychological dependence with repeated use, and its classification as a "weak" opioid obscures a risk profile comparable to low-dose morphine at equianalgesic doses.[6] Its active metabolite carries roughly 70-fold greater receptor affinity than the parent compound,[7] meaning rapid metabolizers face disproportionate overdose risk — a vulnerability invisible without genetic testing. Over a century of clinical use provides a solid evidence base, though formal therapeutic index data remain absent.
History[edit]
Discovery
Dihydrocodeine was developed in Germany in 1908 by reducing the double bond in codeine through catalytic hydrogenation — a straightforward chemical modification that yielded a new analgesic and cough suppressant.[3][8] The compound was first marketed commercially in 1911 and adopted rapidly across Europe due to the simplicity and high yield of its synthesis.
Clinical significance
DHC entered widespread use as a step-2 analgesic on the WHO pain ladder and as an antitussive across Europe. In the United Kingdom, it became the detoxification agent of choice for heroin-dependent patients in community treatment — a role formalized in the Leeds Evaluation of efficacy of Detoxification Study, which compared DHC with buprenorphine in primary care.[4] In Germany, it served both as a therapeutic analgesic and an opioid substitution agent, though patterns of misuse among polydrug-dependent individuals emerged as early as the 1960s.[9]
Regulation and modern era
Accumulating evidence of dependence and misuse led to progressive tightening of DHC's regulatory status across jurisdictions. Pharmacoepidemiological data from England spanning 2001–2020 reveal increasing trends in DHC-implicated overdose fatalities, challenging the long-standing perception of DHC as a low-risk opioid.[5] Pharmacovigilance analyses have confirmed abuse, misuse, and dependence signals warranting continued regulatory attention.[10]
The name dihydrocodeine reflects its chemical origin: the prefix dihydro- indicates saturation of codeine's C7–C8 double bond. In clinical shorthand it is universally referred to as DHC. The compound's reputation as a "weak opioid" — a classification shared with codeine and tramadol — has shaped prescribing culture for decades, encouraging a perception of safety that epidemiological data increasingly contradict.[5]
Chemistry[edit]
Structural class
Dihydrocodeine belongs to the morphinan chemical class — the pentacyclic scaffold shared by morphine, codeine, hydrocodone, and oxycodone. It is produced by semi-synthesis from codeine: catalytic hydrogenation converts the C7–C8 double bond to a single bond, yielding the 7,8-dihydro derivative.[1]
This saturation increases lipophilicity relative to codeine and modestly enhances receptor binding, while preserving the 3-methoxy group that distinguishes the codeine series from the morphine series. The 3-methoxy substitution is pharmacologically significant: enzymatic removal of the methyl group (O-demethylation) converts DHC to dihydromorphine, a metabolite with substantially greater opioid receptor affinity.[7]
Molecular properties
| Molecular formula | C₁₈H₂₃NO₃ |
| Molecular weight | 301.4 g/mol |
The morphinan scaffold comprises five fused rings: a phenanthrene core (rings A, B, C), a piperidine ring (D), and a dihydrofuran ring (E). Key functional groups include the 3-methoxy group (ring A), the 6-hydroxyl group (ring C), and the N-methyl tertiary amine (ring D). The 7,8 bond is fully saturated, distinguishing DHC from codeine.
Stereochemistry
Dihydrocodeine possesses five chirality centers, conferring the natural (−)-morphinan configuration essential for opioid receptor binding. The unnatural (+)-enantiomer lacks significant opioid activity. All pharmaceutical preparations use the single natural enantiomer, most commonly as dihydrocodeine bitartrate.
Pharmacology[edit]
Mechanism of action
Dihydrocodeine activates mu (µ)-, delta (δ)-, and kappa (κ)-opioid receptors, with highest affinity at the mu receptor.[7][11] Mu-receptor activation drives the primary effects: analgesia, euphoria, sedation, and respiratory depression. Delta and kappa contributions are minor at clinical doses.
The 3-methoxy group on the molecule reduces receptor binding compared to the corresponding 3-hydroxy compounds like morphine and dihydromorphine.[11] Despite this reduced affinity, DHC retains direct mu-receptor activity sufficient for clinical analgesia — a meaningful distinction from codeine, which depends more heavily on metabolic conversion to an active form.
Laboratory studies show that DHC stimulates mu-receptor signaling more effectively than codeine,[2] providing a mechanistic explanation for why DHC retains analgesic activity even in individuals who cannot efficiently convert it to dihydromorphine. DHC does not significantly inhibit serotonin or norepinephrine transporters,[12] meaning serotonin syndrome risk in DHC-containing combinations comes from the co-administered agent, not from DHC itself.
Pharmacokinetics
Oral bioavailability is approximately 21%, reflecting substantial first-pass metabolism in the liver.[13] Peak plasma concentration occurs roughly 1.6–1.8 hours after an oral dose, and the half-life is 3.3–4.5 hours.
DHC is metabolized through three parallel pathways. O-demethylation produces dihydromorphine (DHM), the principal active metabolite, which binds mu receptors with approximately 70-fold greater affinity than the parent compound.[7] N-demethylation produces nordihydrocodeine, which has minimal opioid activity.[7] Glucuronidation produces several conjugated metabolites, one of which — DHM-6-O-glucuronide — has high mu-receptor affinity comparable to morphine-6-glucuronide.[14]
Approximately 7% of Caucasians lack the enzyme responsible for converting DHC to dihydromorphine.[7] Unlike codeine, where this genetic variation results in near-complete therapeutic failure, DHC retains meaningful analgesic activity as a parent compound.[1] Liver disease increases oral bioavailability and prolongs drug exposure, requiring dose reduction.[15] Kidney impairment leads to accumulation of active metabolites, with documented cases of prolonged sedation and respiratory depression.[16][17]
Neuroscience[edit]
Reward and reinforcement
Mu-opioid receptor activation in the ventral tegmental area disinhibits dopamine neurons projecting to the nucleus accumbens, producing the reinforcing warmth and euphoria characteristic of opioid agonists. Both DHC and its high-affinity metabolite dihydromorphine activate this pathway. Because dihydromorphine binds mu receptors with roughly 70-fold greater affinity,[7] individuals who metabolize DHC rapidly likely experience substantially greater reinforcement than those who do not — a genetically determined difference in abuse liability that has not been tested in humans.
Pain suppression and respiratory risk
DHC engages descending pain-inhibitory pathways originating in the brainstem, suppressing pain signals at the spinal cord — a mechanism confirmed by its analgesic efficacy across multiple clinical trials.[18][19][3] The same class of receptors in brainstem respiratory centers mediates the respiratory depression that is the primary cause of opioid-related death. Fatal overdose cases show elevated dihydromorphine concentrations at post-mortem,[20][14] indicating that metabolite-driven respiratory depression contributes to lethality even when parent compound levels appear moderate.
Several questions remain unanswered. Whether genetic variation in DHC metabolism produces measurably different subjective reward — and therefore different addiction trajectories — has not been studied in humans. The role of DHM-6-O-glucuronide in prolonged opioid effects, particularly in kidney impairment, lacks pharmacodynamic characterization.[14] Whether rising DHC-related mortality trends[5] reflect pharmacological factors, prescribing patterns, or changing polydrug use remains unresolved.
Subjective Effects[edit]
Dihydrocodeine produces a warm, enveloping body sensation accompanied by pain suppression, mild euphoria, and a quieting of mental activity. The overall character is sedation and contentment rather than stimulation. Set and setting modulate the experience less dramatically than with psychedelics — the pharmacological floor of μ-opioid agonism is relatively consistent — though pre-existing pain, anxiety, and opioid tolerance substantially alter perceived intensity.
Within the opioid class, DHC sits closest to codeine in experiential character — a mild, manageable warmth with modest euphoria — but with slightly greater reliability owing to its intrinsic mu-receptor activity independent of metabolic conversion. Compared to morphine, the subjective ceiling is lower and the experience qualitatively thinner, lacking the depth of euphoria and heavy nodding sedation associated with higher-affinity agonists.
Effect Grid
At 100–150 mg oral, clear opioid effects emerge — a noticeable warmth envelops the body, moderate sedation sets in, and mild euphoria becomes apparent. Anxiety suppression is reliable, and cognitive euphoria manifests as quiet contentment. Thought deceleration is more pronounced, and emotional suppression may blunt affect.
Physically, constipation is likely, pupil constriction is marked, and dry mouth is reported in approximately 80% of individuals at similar clinical doses (Freye 2001). Nausea becomes more common. Pain suppression is significant. Spontaneous body sensations — warmth and tingling — are characteristic.
Driving and operating machinery are inadvisable. Duration is approximately 4–6 hours for immediate-release formulations. CYP2D6 genotype modulates intensity — ultrarapid metabolizers experience disproportionately greater effects.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Dreaming enhancement · Proprioceptive distortion · Spatial disorientation · Visual haze / noise
Constipation · Bodily heaviness · Body high · Muscle relaxation · Physical fatigue · Spontaneous body sensations · Dizziness · Nausea · Tactile euphoria · Sexual arousal suppression · Dry mouth · Excessive sweating · Yawning · Appetite suppression · Nasal congestion · Temperature dysregulation · Vomiting · Watery eyes · Abnormal heartbeat · Heart rate perception changes · Tingling / electric sensations · Bodily dissociation
Muscle relaxation · Physical fatigue · Spontaneous body sensations · Dizziness · Nausea · Tactile euphoria · Sexual arousal suppression · Dry mouth · Excessive sweating · Yawning · Appetite suppression · Nasal congestion · Vomiting · Watery eyes · Abnormal heartbeat · Heart rate perception changes · Tingling / electric sensations · Bodily dissociation
Cognitive euphoria · Focus suppression · Thought deceleration · Analysis suppression · Memory suppression · Confusion · Delusions of sobriety · Language suppression · Motivation suppression · Thought disorganization · Memory fragmentation · Delirium
Analysis suppression · Memory suppression · Confusion · Language suppression · Motivation suppression · Thought disorganization · Memory fragmentation · Delirium
Sociability suppression · Sociability enhancement · Cognitive disconnection
Timeline
Initial absorption phase with minimal perceptible effect. A faint awareness of something shifting may be noticed.
Gradual emergence of warmth, anxiety suppression, and mild euphoria as plasma concentrations rise toward Tmax (1. 6–1. 8 hours).
Full opioid effect — maximal analgesia, sedation, euphoria, and pupil constriction. Corresponds to Tmax and early elimination phase.
Sustained but gradually diminishing effects as plasma levels decline through the 3. 3–4. 5 hour elimination half-life.
Effects fade progressively. Sedation and constipation may linger while euphoria and analgesia dissipate.
Residual mild sedation and subtle warmth. Constipation may persist beyond other effects.
⚠ Avoid driving or operating machinery for at least 6 hours after dosing, or longer if sedation persists.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- opioids
Toxicity
Acute toxicity
DHC overdose causes slowed breathing, pinpoint pupils, low blood pressure, and loss of consciousness — progressing to coma and death in severe cases. No formal lethal dose or therapeutic index has been established.
Rising overdose fatality data from England spanning 2001–2020 challenge the long-standing view of DHC as a low-risk opioid.[4] Post-mortem analysis of fatal cases consistently shows elevated dihydromorphine concentrations[20][14] — the metabolite contributes to death even when DHC levels appear low. A documented case of a 1-month-old infant receiving prescribed DHC developed respiratory depression from immature liver metabolism producing disproportionately high drug concentrations.[21]
Chronic toxicity
Kidney impairment leads to accumulation of active metabolites, with documented cases of prolonged sedation and respiratory depression.[15][16] Constipation is driven by opioid receptors in the gut and does not improve with dose reduction.[22] At equivalent doses, DHC carries no less risk than low-dose morphine for respiratory depression and dependence.[5]
Psychological risks
Psychological dependence develops with repeated use — compulsive drug-seeking and craving. Pharmacovigilance databases confirm abuse, misuse, and dependence signals,[9] and compulsive use patterns were documented in Germany from the 1960s onward.[8]
Increased pain sensitivity during chronic use (opioid-induced pain enhancement) is a class-level risk expected to apply to DHC. Sedation, thought deceleration, and impaired coordination occur acutely and may persist with chronic use.
Tolerance and dependence
Tolerance to DHC's pain-relieving, euphoric, and respiratory effects develops with repeated use through standard opioid receptor adaptation. Cross-tolerance exists with all opioids.
Physical dependence is documented through DHC's use in opioid substitution programs — the Leeds detoxification study used DHC as its standard comparator, confirming it produces opioid-type physical dependence amenable to structured tapering.[3] Withdrawal follows the standard short-acting opioid pattern: anxiety, restlessness, muscle pain, runny nose, insomnia, diarrhea, nausea, and cravings.inferred
Drug Interactions
The most dangerous interactions involve additive depression of breathing and the central nervous system.
Alcohol: Combined opioid and sedative effects add together to slow breathing dangerously. Lethal risk.[5]
GHB and GBL: Additive central nervous system depression through combined opioid and GABA mechanisms. Lethal risk.
Ketamine: Additive respiratory and central nervous system depression. Lethal risk.
Tramadol: Additive opioid respiratory depression; tramadol's additional serotonin activity[12] introduces theoretical serotonergic risk when other serotonergic agents are also present. Lethal risk primarily from respiratory depression.
Benzodiazepines: Additive respiratory and central nervous system depression through combined opioid and GABA-A mechanisms. Lethal risk.citation needed
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion): Reduce conversion of DHC to its high-affinity metabolite, potentially decreasing both therapeutic effect and toxicity.
MAO inhibitors: Class-level caution — concurrent use with opioids carries risk of unpredictable reactions.citation needed
Contraindications
10 knownAbsolute contraindications:
- Respiratory insufficiency: DHC-induced respiratory depression is the primary mechanism of death; pre-existing breathing problems increase this risk substantially.
- Severe liver impairment: Reduced metabolism increases drug exposure and prolongs effects.[17][23]
- Severe kidney impairment: Active metabolites accumulate, causing prolonged sedation and respiratory depression.[15][16][24]
- Concurrent MAO inhibitor use: Class-level contraindication for opioids.
- Neonates and infants: Immature liver metabolism produces disproportionate drug accumulation.[21]
Relative contraindications:
- Rapid metabolizer status: Excessive dihydromorphine formation increases respiratory depression and overdose risk at standard doses.
- Concurrent depressant use: alcohol, benzodiazepines, and other sedatives amplify respiratory depression.
- History of opioid use disorder: DHC produces reinforcement and dependence through the brain's mesolimbic pathway.
- Raised pressure inside the skull: Opioid-induced CO₂ retention can worsen the condition.
- Bowel obstruction: DHC reduces gut motility.[22]
Harm Reduction[edit]
Forms & Identification
DHC circulates almost exclusively as pharmaceutical tablets — immediate-release (typically 30 mg) and controlled-release (60–120 mg, branded DHC Continus in the UK). Combination products pairing low-dose DHC with paracetamol are the most common over-the-counter form.
Because DHC is usually pharmaceutical-grade, adulteration risk is lower than for unregulated opioids. The key identification concern is preparation type: controlled-release tablets must never be crushed, split, or chewed — this defeats the sustained-release mechanism and delivers the full dose at once.
Guidelines
- Start with the lowest effective dose and wait for full onset (1.5–2 hours) before considering redosing.
- Never crush or chew controlled-release formulations.
- Avoid use on consecutive days to slow tolerance development.
- Keep naloxone accessible when using any opioid.
- Do not use alone — respiratory depression can render a person unable to call for help.
- Eat lightly before dosing to reduce nausea; stay hydrated throughout.
- If using paracetamol-containing combination products, track total paracetamol intake — the maximum safe daily dose is 4 g, and liver damage from paracetamol overdose can be fatal.
Set & Setting
Opioid effects are less context-dependent than psychedelics, but environment still matters. A calm, comfortable setting reduces anxiety-driven dose escalation. Having a sober, trusted person present is advisable — particularly at higher doses or when combining with any other substance.
A history of depression, anxiety, or emotional distress increases the risk that opioid euphoria creates a powerful association between the substance and relief — one of the primary drivers of psychological dependence.
Aftercare & integration. After opioid use, the primary concerns are physical recovery and honest self-assessment. Constipation may persist for 24–48 hours; hydration, fiber, and gentle movement help. Mild rebound effect pain or irritability the following day is normal and does not require redosing.
Use patterns deserve honest monitoring. If doses are increasing, intervals are shortening, or the substance is being used to manage emotions rather than pain, these are early signs of problematic use. A written log of use — dates, doses, and reasons — makes patterns visible before they become entrenched.
Recovery & Support
Physical dependence on DHC develops with regular use and requires structured tapering rather than abrupt cessation. Medical supervision for withdrawal is recommended — healthcare providers can prescribe tapering schedules or substitution agents (buprenorphine, methadone) appropriate to the level of dependence.
Support resources include opioid-specific mutual aid groups (SMART Recovery, Narcotics Anonymous), addiction medicine specialists, and in the UK, community drug treatment services with specific experience managing DHC dependence. Dependence is a physiological adaptation, not a moral failure — seeking help early produces better outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing has slowed to fewer than 8 breaths per minute, or stopped
- Lips, fingernails, or skin turning blue or grey
- Unresponsive to voice or pain (sternal rub)
- Gurgling, choking, or snoring sounds while unconscious
Immediate steps:
- 1. Call emergency services immediately.
- 2. Administer naloxone if available — intranasally or intramuscularly per the kit's instructions.
- 3. Place the person in the recovery position (on their side) to prevent choking.
- 4. If breathing stops and trained to do so, begin rescue breathing.
- 5. Stay with the person. Naloxone wears off in 30–90 minutes — opioid effects may return, requiring a second dose.
- 6. Do NOT induce vomiting. Do NOT leave the person alone.
What to tell the dispatcher: the substance taken (dihydrocodeine/opioid), the approximate amount and time, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during an overdose.
Reversal agent: Naloxone (Narcan) reverses opioid-induced respiratory depression. It is available without prescription in many jurisdictions and should be kept accessible whenever opioids are used.
Legal Status[edit]
Dihydrocodeine is internationally controlled as a Schedule II narcotic under the United Nations Single Convention on Narcotic Drugs (1961),[7] with national scheduling varying considerably — particularly between pure DHC and low-dose combination products.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | Pure dihydrocodeine. Some combination products carry lower scheduling.[7] |
| United Kingdom | Class B (Misuse of Drugs Act 1971); Schedule 5 (Misuse of Drugs Regulations 2001) | Available OTC as combinations containing fewer than 8 mg DHC per unit with paracetamol. Schedule 5 exemption applies to preparations containing ≤100 mg per preparation (≤2.5%) not designed for injection.[7] |
| Germany | Betäubungsmittelgesetz (BtMG) | Controlled under narcotic law. Historically used as a registered substitution agent for opioid dependence.[7] |
| Australia | Schedule 8 (pure); Schedule 4 (combination, ≤100 mg/dose); Schedule 3 (cough preparations, ≤15 mg/dose) | Tiered scheduling based on preparation type and dose.[7] |
| Canada | Controlled (prescription required) | Listed under the Controlled Drugs and Substances Act.safety citation needed |
| International | UN Single Convention on Narcotic Drugs (1961), Schedule II | Internationally controlled narcotic substance.[7] |
Legal status varies by jurisdiction and changes over time. The information above is a general overview and does not constitute legal advice.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- opioids
Toxicity
Acute toxicity
Dihydrocodeine overdose produces slowed breathing, pinpoint pupils, low blood pressure, and decreased consciousness, progressing to coma and death in severe cases. No formal lethal dose or therapeutic index has been established.
Rising DHC-implicated fatalities in England from 2001 to 2020 challenge its classification as a "weak" opioid with an inherently favorable safety margin.[5] Post-mortem analyses from fatal overdoses consistently show elevated dihydromorphine concentrations,[20][14] indicating that this active metabolite contributes significantly to lethality even when parent compound levels appear low.
In a documented case, a 1-month-old infant receiving prescribed DHC developed respiratory depression due to immature liver metabolism, producing disproportionately high drug concentrations.[21]
Chronic toxicity
No specific liver toxicity from DHC has been described. Kidney impairment leads to accumulation of active metabolites, with documented cases of prolonged sedation and respiratory depression.[16][17]
Constipation occurs through opioid receptor activation in the gut and is dose-independent — it does not improve with dose adjustment.[22] Hormonal disruption (reduced sex hormones, cortisol suppression) is a class effect expected with chronic use, though no DHC-specific data exist.
At equianalgesic doses, DHC carries no less risk than low-dose morphine for respiratory depression, constipation, and dependence.[6]
Psychological risks
Psychological dependence develops with repeated use, manifesting as compulsive drug-seeking and craving. Pharmacovigilance databases confirm abuse, misuse, and dependence signals for DHC.[10] Historical data from Germany document compulsive DHC use patterns among polydrug-dependent individuals since the 1960s.[9]
Increased pain sensitivity during chronic use (opioid-induced pain enhancement) is a class-level risk expected to apply to DHC, though no DHC-specific studies exist. Cognitive impairment — sedation, thought deceleration, and impaired coordination — occurs acutely and may persist with chronic use.
Tolerance and dependence
Tolerance to DHC's pain-relieving, euphoric, and respiratory-depressant effects develops with repeated use through standard μ-opioid adaptation mechanisms. Cross-tolerance exists with all opioids.
Specific tolerance timelines for DHC have not been established in published studies. Physical dependence is documented through DHC's clinical use in opioid substitution programs — the Leeds detoxification study used DHC as its standard protocol, confirming that it produces opioid-type physical dependence amenable to structured tapering.[4]
Withdrawal follows the standard short-acting opioid pattern: anxiety, restlessness, muscle pain, runny nose, yawning, insomnia, diarrhea, nausea, and cravings.inferred
Drug Interactions
The most dangerous interactions involve additive respiratory and central nervous system depression with other depressant substances.
Alcohol: Combined mu-opioid and sedative effects produce additive respiratory depression. Lethal risk.[6]
GHB and GBL: Additive central nervous system depression through combined opioid and GABA-B mechanisms. Lethal risk.
Ketamine: Additive respiratory and central nervous system depression. Lethal risk.
Tramadol: Additive opioid respiratory depression, with tramadol's additional serotonin activity[12] introducing theoretical serotonergic risk when other serotonergic agents are also present. Lethal risk primarily from respiratory depression.
Benzodiazepines: Additive respiratory and central nervous system depression through combined opioid and GABA-A mechanisms. Lethal risk.citation needed
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion): Reduce conversion of DHC to its high-affinity metabolite, potentially decreasing both therapeutic effect and toxicity.
MAO inhibitors: Class-level caution — concurrent use with opioids carries risk of unpredictable reactions.citation needed
Contraindications
10 knownAbsolute contraindications:
- Respiratory insufficiency: DHC-induced respiratory depression is the primary mechanism of death; pre-existing breathing problems increase this risk substantially.
- Severe liver impairment: Reduced metabolism increases drug exposure and prolongs effects.[15][23]
- Severe kidney impairment: Active metabolites accumulate, producing prolonged sedation and respiratory depression.[16][17][24]
- Concurrent MAO inhibitor use: Class-level contraindication for opioids.
- Neonates and infants: Immature liver metabolism produces disproportionate drug accumulation.[21]
Relative contraindications:
- Rapid metabolizer status: Excessive dihydromorphine formation increases respiratory depression and overdose risk at standard doses.
- Concurrent depressant use: alcohol, benzodiazepines, and other sedatives amplify respiratory depression.
- History of opioid use disorder: DHC produces reinforcement and dependence through the brain's mesolimbic pathway.
- Raised pressure inside the skull: Opioid-induced CO₂ retention can worsen the condition.
- Bowel obstruction: DHC reduces gut motility.[22]
Harm Reduction[edit]
Forms & Identification
DHC circulates almost exclusively as pharmaceutical tablets — immediate-release (typically 30 mg, small round tablets) and controlled-release formulations (60–120 mg, branded as DHC Continus in the UK). Combination products pairing low-dose DHC with paracetamol are the most commonly encountered over-the-counter form.
Because DHC is usually pharmaceutical-grade, adulteration risk is lower than for unregulated opioids. The primary identification concern is confirming the preparation type: controlled-release tablets must never be crushed, split, or chewed, as this defeats the sustained-release mechanism and delivers the full dose at once.
Guidelines
- Start with the lowest effective dose and wait for full onset (1.5–2 hours) before considering redosing.
- Never crush or chew controlled-release formulations.
- Avoid use on consecutive days to slow tolerance development.
- Keep naloxone accessible when using any opioid.
- Do not use alone — respiratory depression can render a person unable to call for help.
- Eat lightly before dosing to reduce nausea; stay hydrated throughout.
- If using paracetamol-containing combination products, track total paracetamol intake — the maximum safe daily dose is 4 g, and liver damage from paracetamol overdose can be fatal.
Set & Setting
Opioid effects are less context-dependent than psychedelics, but environment still matters. A calm, comfortable setting reduces anxiety-driven dose escalation. Having a sober, trusted person present is advisable, particularly at higher doses or when combining with any other substance.
Individuals with a history of depression, anxiety, or emotional distress should be aware that opioid euphoria can create a powerful association between the substance and relief — one of the primary drivers of psychological dependence.
Aftercare & integration. After opioid use, the primary aftercare concerns are physical recovery and honest self-assessment. Constipation may persist for 24–48 hours; hydration, fiber, and gentle movement help. Mild rebound effect pain or irritability the following day is normal and does not require redosing.
Monitor your own use patterns honestly. If doses are increasing, intervals are shortening, or the substance is being used to manage emotions rather than pain, these are early signs of problematic use. Keeping a written log of use — dates, doses, and reasons — makes patterns visible before they become entrenched.
Recovery & Support
Physical dependence on DHC develops with regular use and requires structured tapering rather than abrupt cessation. Medical supervision for withdrawal is recommended — healthcare providers can prescribe tapering schedules or substitution agents (buprenorphine, methadone) appropriate to the level of dependence.
Support resources include opioid-specific mutual aid groups (SMART Recovery, Narcotics Anonymous), addiction medicine specialists, and in the UK, community drug treatment services with specific experience managing DHC dependence. Dependence is a physiological adaptation, not a moral failure — seeking help early produces better outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing has slowed to fewer than 8 breaths per minute, or stopped
- Lips, fingernails, or skin turning blue or grey
- Unresponsive to voice or pain (sternal rub)
- Gurgling, choking, or snoring sounds while unconscious
Immediate steps:
- 1. Call emergency services immediately.
- 2. Administer naloxone if available — intranasally or intramuscularly per the kit's instructions.
- 3. Place the person in the recovery position (on their side) to prevent choking.
- 4. If breathing stops and you are trained, begin rescue breathing.
- 5. Stay with the person. Naloxone wears off in 30–90 minutes — opioid effects may return, requiring a second dose.
- 6. Do NOT induce vomiting. Do NOT leave the person alone.
What to tell the dispatcher: the substance taken (dihydrocodeine/opioid), the approximate amount and time, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during an overdose.
Reversal agent: Naloxone (Narcan) reverses opioid-induced respiratory depression. It is available without prescription in many jurisdictions and should be kept accessible whenever opioids are used.
Legal Status[edit]
Dihydrocodeine is internationally controlled under the United Nations Single Convention on Narcotic Drugs (1961), where it is listed as a Schedule II substance.[8] National scheduling varies considerably, with several jurisdictions distinguishing between pure DHC and low-dose combination products.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | Pure dihydrocodeine. Some combination products carry lower scheduling.[8] |
| United Kingdom | Class B (Misuse of Drugs Act 1971); Schedule 5 (Misuse of Drugs Regulations 2001) | Available OTC as combinations containing fewer than 8 mg DHC per unit with paracetamol. Schedule 5 exemption applies to preparations containing ≤100 mg per preparation (≤2.5%) not designed for injection.[8] |
| Germany | Betäubungsmittelgesetz (BtMG) | Controlled under narcotic law. Historically used as a registered substitution agent for opioid dependence.[8] |
| Australia | Schedule 8 (pure); Schedule 4 (combination, ≤100 mg/dose); Schedule 3 (cough preparations, ≤15 mg/dose) | Tiered scheduling based on preparation type and dose.[8] |
| Canada | Controlled (prescription required) | Listed under the Controlled Drugs and Substances Act.safety citation needed |
| International | UN Single Convention on Narcotic Drugs (1961), Schedule II | Internationally controlled narcotic substance.[8] |
Frequently asked questions
What is Dihydrocodeine?
Dihydrocodeine is a semi-synthetic opioid analgesic of the morphinan class, derived from codeine by hydrogenation of the C7–C8 bond. It acts primarily as a mu-opioid receptor agonist, with clinical use since 1911 for analgesia and cough suppression.
How long does Dihydrocodeine last?
Total duration by route of administration — Oral: 4 – 6 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Dihydrocodeine?
Psychedex publishes a dosage table for Dihydrocodeine on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Dihydrocodeine?
The highest-severity documented interactions for Dihydrocodeine: Benzodiazepines, Barbiturates (Lethal), GHB, Baclofen (Lethal), GHB, GBL (Lethal), Local anesthetics (Lethal), 5-HTP, Tryptophan (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Dihydrocodeine addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Dihydrocodeine: tolerance builds moderate; full reset takes 10.5 days; cross-tolerance develops with opioids. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abThompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE (2004) Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. — The Journal of pharmacology and experimental therapeutics PMID:14600248
- [2] ^abcEdwards JE, McQuay HJ, Moore RA (2000) Single dose dihydrocodeine for acute postoperative pain. — The Cochrane database of systematic reviews PMID:11034754
- [3] ^abcOldham NS, Wright NM, Adams CE, Sheard L, Tompkins CN (2004) The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) project. — BMC family practice PMID:15117415
- [4]
- [5] ^abcPrescrire International (2016) 'Weak' opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphine — Prescrire International PMID:27042732
- [6]
references
- [1] ^abcLeppert W, Woron J (2016) Dihydrocodeine: safety concerns. — Expert review of clinical pharmacology doi:10.1586/17512433.2016.1092871
- [2] ^abThompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE (2004) Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. — The Journal of pharmacology and experimental therapeutics PMID:14600248
- [3] ^abcEdwards JE, McQuay HJ, Moore RA (2000) Single dose dihydrocodeine for acute postoperative pain. — The Cochrane database of systematic reviews PMID:11034754
- [4] ^abcOldham NS, Wright NM, Adams CE, Sheard L, Tompkins CN (2004) The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) project. — BMC family practice PMID:15117415
- [5]
- [6] ^abcPrescrire International (2016) 'Weak' opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphine — Prescrire International PMID:27042732